Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis
Brief Summary: The primary objective of this study is to determine the efficacy of peginterferon beta-1a in reducing the annualized relapse rate (ARR) in participants with relapsing multiple sclerosis (RMS) at 1 year. The secondary objectives of this study are to determine whether peginterferon beta-1a, at 1 year when compared with placebo, is effective in reducing the total number of new or newly enlarging T2 hyperintense lesions on brain magnetic resonance imaging (MRI) scans, reducing the proportion of participants who relapse, and slowing the progression of disability.


Options:
A: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: BIIB017 (peginterferon beta-1a), Drug: Placebo | Arm Label: Peginterferon Beta-1a Q2W; Type: EXPERIMENTAL; Interventions: Drug: BIIB017 (peginterferon beta-1a) | Arm Label: Peginterferon Beta-1a Q4W; Type: EXPERIMENTAL; Interventions: Drug: BIIB017 (peginterferon beta-1a), Drug: Placebo | Intervention Type: DRUG; Name: BIIB017 (peginterferon beta-1a); Assigned to Arm(s): Peginterferon Beta-1a Q2W, Peginterferon Beta-1a Q4W, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Peginterferon Beta-1a Q4W, Placebo
C: Arm Label: Cladribine Low/Placebo (LLPP); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cladribine High Dose/Placebo (HLPP); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cladribine Low/Low Dose (LLLL); Type: EXPERIMENTAL; Interventions: Drug: Cladribine | Arm Label: Cladribine High/Low Dose (HLLL); Type: EXPERIMENTAL; Interventions: Drug: Cladribine | Arm Label: Placebo/Cladribine Low Dose (PPLL); Type: EXPERIMENTAL; Interventions: Drug: Cladribine | Arm Label: Placebo/No Treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Cladribine 3.5 mg/kg/No Treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Cladribine 5.25 mg/kg/No Treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Cladribine; Assigned to Arm(s): Cladribine Low/Low Dose (LLLL) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cladribine Low/Placebo (LLPP) | Intervention Type: DRUG; Name: Cladribine; Assigned to Arm(s): Cladribine High/Low Dose (HLLL) | Intervention Type: DRUG; Name: Cladribine; Assigned to Arm(s): Placebo/Cladribine Low Dose (PPLL) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cladribine High Dose/Placebo (HLPP)
D: Arm Label: Daclizumab High Yield Process 150 mg SC; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process), Drug: Interferon beta-1a Placebo | Arm Label: IFN β-1a 30 µg IM; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a, Drug: Daclizumab High Yield Process Placebo | Intervention Type: BIOLOGICAL; Name: BIIB019 (Daclizumab High Yield Process); Assigned to Arm(s): Daclizumab High Yield Process 150 mg SC | Intervention Type: DRUG; Name: Interferon beta-1a Placebo; Assigned to Arm(s): Daclizumab High Yield Process 150 mg SC | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): IFN β-1a 30 µg IM | Intervention Type: DRUG; Name: Daclizumab High Yield Process Placebo; Assigned to Arm(s): IFN β-1a 30 µg IM

Answer: B